TITLE: Baseline Predictors of Remission, Pain and Fatigue in Rheumatoid Arthritis: The TITRATE Trial

SHORT TITLE: Baseline Outcome Predictors in Rheumatoid Arthritis Trial

AUTHORS
Sook Yan Lee MBBS, MRCP(UK) ¹
Fowzia Ibrahim PhD ¹
Brian DM Tom PhD ²
Elena Nikiphorou MD¹
Frances MK Williams PhD³
Heidi Lemp PhD¹
David L Scott MD¹

1. Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, Cutcombe Road, London, SE5 9RJ, UK

2. MRC Biostatistics Unit, University of Cambridge, East Forvie Building, Forvie Site, Robinson Way, Cambridge Biomedical Campus, Cambridge, CB2 0SR, UK

3. Twin Research & Genetic Epidemiology, School of Life Course Sciences, King’s College London, St Thomas' Hospital, London SE1 7EH, UK

CORRESPONDING AUTHOR
Name Dr Sook Yan Lee
Address Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, Cutcombe Road, London, SE5 9RJ, UK
Telephone +44 780 5260 565
Email: sookyan@doctors.org.uk
ORCID iD 0000-0003-2074-6785

WORD COUNTS, TABLES AND FIGURES
Abstract: 249
Main Text: 3031
References: 47
Figures: 1
Tables: 4 in main article; 5 in supplementary material
DECLARATIONS

Ethics Approval and Consent to Participate
The TITRATE trial was ethically approved from the London – West London & GTAC National Research Ethics Service (NRES) Committee (13/LO/1308).

Trial Registration
ISRCTN: 70160382; date registered 16 January 2014

Consent for Publication
Not applicable

Availability of Data and Materials
The dataset analysed is not publicly available because data sharing was not part of the original consent and requires institutional approval, but data requests should be submitted to the corresponding author and summary data may be granted following review.

Competing Interests
EN has received speaker honoraria/participated in advisory boards for Pfizer, AbbVie, Sanofi, Gilead, Celltrion and Lilly. Other authors have no conflicts of interest to report.

Funding
This study was funded by the National Institute for Health Research (NIHR) [Programme Grants for Applied Research (Grant Reference Number RP-PG-0610-10066)]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

BT is supported by the UK Medical Research Council (Unit Programme number MC_UP_1302/3 & MRC_MC_UU_00002/2) and by the NIHR Cambridge Biomedical Research Centre

Author’s Contributions
SYL and FI designed and conceptualized the study, analysed and drafted the manuscript. DS, BT, EN, FW and HL contributed towards interpreting the data and approved the final manuscript.

Acknowledgements
Not applicable
ABSTRACT

Background
Clinical trials show intensive treatment to induce remission is effective in patients with highly active rheumatoid arthritis (RA). The TITRATE trial showed that the benefits of intensive treatment also extend to moderately active RA. However, many patients failed to achieve remission or show improvements in pain and fatigue. We investigated whether baseline predictors could identify treatment non-responders.

Methods
The impact of obesity, depression, anxiety and illness perception on RA outcomes, including disease activity, remission, pain and fatigue were determined using a pre-planned secondary analysis of the TITRATE trial data.

Results
Body mass index was associated with disease activity levels and remission: obese patients had a higher overall disease activity and fewer obese patients achieved remission. Intensive management was not associated with increased remission in these patients. Obesity was also associated with increased overall pain and fatigue. Anxiety, depression and health perceptions had no discernible impact on disease activity but were associated with high levels of pain and fatigue. There was a strong association between anxiety and high pain scores; and between depression and high fatigue scores; and health perception was strongly related to both. None of the predictors had an important impact on pain and fatigue reduction in cross-sectional analysis.

Conclusions
Disease activity is higher in obese patients and they have fewer remissions over 12 months. Anxiety, depression and health perceptions were associated with higher pain and fatigue scores. Intensive management strategies need to account for these baseline features as they impact significantly on clinical and psychological outcomes.
SIGNIFICANCE AND INNOVATIONS

- Patients with moderately active RA respond heterogeneously to intensive treatment.
- Disease activity is higher in obese patients: they also have a lower chance of remission.
- Anxiety, depression and health perception are associated with higher pain and fatigue scores.
- Intensive treatment strategies need to account for baseline obesity, psychological status and illness perceptions.

KEYWORDS

- Anxiety
- Depression
- Disease Activity Score
- Fatigue
- Intensive Management
- Obesity
- Pain
- Rheumatoid Arthritis
# LIST OF ABBREVIATIONS

| Abbreviation | Description |
|--------------|-------------|
| BIPQ         | Brief Illness Perceptions Questionnaire |
| BMI          | Body Mass Index |
| CDAI         | Clinical Disease Activity Index |
| CI           | Confidence Interval |
| csDMARD      | Conventional Synthetic Disease Modifying Anti-Rheumatic Drug |
| DAS28        | Disease Activity Score For 28 Joints |
| DAS28-ESR    | Disease Activity Score for 28 Joints based on ESR |
| DMARDs       | Disease Modifying Anti-Rheumatic Drugs |
| ESR          | Erythrocyte Sedimentation Rate |
| GAD-7        | Generalized Anxiety Disorder-7 |
| IM           | Intensive Management |
| NHS          | National Health Service |
| NRES         | National Research Ethics Service |
| OR           | Odds Ratio |
| PHQ-9        | Patient Health Questionnaire-9 |
| RA           | Rheumatoid Arthritis |
| SC           | Standard Care |
| SD           | Standard Deviation |
| SDAI         | Simple Disease Activity Index |
| TITRATE      | Treatment Intensities and Targets in Rheumatoid Arthritis Therapy Trial |
| WHO          | World Health Organization |
BACKGROUND

Key treatment goals in rheumatoid arthritis (RA) include minimising disease activity by achieving remission, decreasing disability and improving health related quality of life [1]. In patients with active RA, particularly those with early disease, intensive treatment using treat-to-target approaches, achieves these goals in many patients [2]. There is more uncertainty whether intensive treatment is equally beneficial in patients with RA with established disease who only have moderate disease activity. The Treatment Intensities and Targets in Rheumatoid Arthritis Therapy (TITRATE) trial assessed whether patients with moderate disease activity would also benefit from intensive treatment [3, 4] in combination with psychosocial support. TITRATE confirmed that intensive treatment does increase remission rates in patients with moderately active established disease.

There is growing recognition that many patients fail to respond to intensive treatments using treat-to-target approaches and understanding the reasons for treatment failure remains an important research objective. There is strong evidence that obesity is a factor influencing response to treatment in RA [5]. In addition, depression and mental health status can influence RA clinical outcomes [6]. Therefore, we evaluated the impact of baseline obesity, mental health status and health perceptions on key clinical outcomes in the TITRATE trial. We focused on three main outcomes: disease activity score, pain, fatigue, and evaluated not only the overall scores, but also important endpoints spanning remission and minimal clinical improvements in pain and fatigue.
METHODS

Study Design

The TITRATE trial protocol and the main trial paper have been published [3, 4]. In brief, the trial design was an open-label, 12-month, pragmatic, randomised, multicentre, two-arm, parallel group superiority trial. The TITRATE trial was ethically approved from the London – West London & GTAC National Research Ethics Service (NRES) Committee (13/LO/1308).

Participants

Participants were recruited from 39 specialist rheumatology centres across England over 18 years; who met 2010 RA classification criteria [7]; had received ≥6 months conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs); were currently receiving at least one csDMARD; had intermediate disease activity score based on Erythrocyte Sedimentation Rate (DAS28-ESR 3.2-5.1 with at least one swollen joint). Participants were randomised to a Standard Care (SC) arm or an Intensive Management (IM) arm, patients in the IM arm received a combination of psychosocial support and drug treatment as per an agreed treatment algorithm. The intervention was delivered by nurses and allied healthcare professionals who completed a 2-day training course on delivering intensive management using motivational interviewing techniques and followed a pre-defined treatment support programme [8-10].

Assessments

Baseline predictors included depression and anxiety measured by Patient Health Questionnaire-9 (PHQ-9) [11] and Generalised Anxiety Disorder-7 (GAD-7) [12], health
perception assessed by the Brief Illness Perceptions Questionnaire (BIPQ) [13] and body mass index (BMI, kg/m²).

Statistical Methods

All the baseline variables were complete. Remission at 12 months was defined as a 12-month DAS28-ESR < 2.6; Δ pain at 12 months was calculated as change in pain score between 12 months and baseline, then it was categorised into two groups (achieving ≥10-unit improvement in pain =1; achieving <10-units worsening in pain =0). At least 10-unit improvement from baseline is classed as a minimal clinical improvement in pain [14]. Similarly, Δ fatigue at 12 months was calculated as change in fatigue score between 12 months and baseline, then it was categorized into two groups (achieving ≥10-unit improvement in fatigue =1; achieving <10-units worsening in fatigue =0) [15]. Some patients had missing 12-month outcome data, so this analysis was restricted to patients in whom a 12-month DAS28-ESR, pain and fatigue scores were available (n=299/335 (89%)).

Body mass index (BMI) was calculated as the total body weight (kg) divided by the square of height (m²). BMI was categorised according to standard World Health Organization (WHO) definitions: Normal = 18.5 to 24.9, Overweight = 25.0 to 29.9 and Obese ≥ 30.0 kg/m². Of note, there were no patients in this trial who were underweight at <18.5 kg/m².

The depression scale (PHQ-9) was categorised as Mild = 0-5; Moderate = 6-10; Moderately Severe = 11-15 and Severe Depression = 16-20 [11]. Similarly, the anxiety scale (GAD7) was categorised into Mild = 0-5; Moderate = 6-10; Moderately Severe = 11-15 and Severe Anxiety = 16-21 score [12].

Univariable and multivariable logistic regression models were fitted for each binary outcome corresponding to remission, fatigue and pain. Baseline predictors, significant at the 5% level
in univariable analyses, were included in multivariable models. In addition, demographic variables (age, gender, ethnicity, disease duration, NHS region) including the trial arm, were adjusted for in the multivariable models. Odds ratios (OR) and 95% confidence intervals (CI) were reported for each model.

Furthermore, separate mixed effects models were fitted to each of the three continuous outcomes – DAS28, pain and fatigue. The longitudinal models captured the temporal change at three-time points - baseline, 6 and 12 months. Working correlation matrices were unstructured. Interactions between time and randomised group were assessed in these models. The estimates (β coefficients) of magnitude and direction of change in the outcome variables associated with differences in baseline predictor variables, with 95% CI, were reported. All models included random intercepts to account for variation in the outcome variable across individual patients. Follow-up time was included as a factor variable. A random time slope was assessed but found not to be needed as assessed by the likelihood ratio test, thus the final mixed models included only random intercepts as random effect terms. A mixed effect model dealt with missing outcome data under the missing at random assumption; all patients were included in our analyses, as baseline data were fully observed [16]. Analyses were undertaken using Stata 16 [17].
RESULTS

Patients Studied

Between August 2014 and July 2017, 459 patients were screened and 335 randomised and treated in the TITRATE trial: 168 patients (140 females) received intensive management and 167 (130 females) had standard care; 12-month follow up data were available for 134 patients who received intensive management and 124 patients who received standard care. Mean age was 56 years (SD 12) for both groups. Mean disease duration was 7 years (SD 7) for intensive management patients and 5 years (SD 5) for patients receiving standard care (Supplementary Table 1).

Baseline Predictors, DAS28, Pain and Fatigue Levels over 12 months (Longitudinal Analysis)

Longitudinal analyses using mixed effects models showed patients who were obese at baseline had higher mean DAS28, pain and fatigue scores compared to non-obese patients during the follow-up period. These differences remained significant after adjusting for age, gender, ethnicity, trial arm, disease duration and NHS region (Table 1).

Depression and anxiety were found to be weakly associated with DAS28-ESR in unadjusted models, but the effects became non-significant on adjustment (Tables 2 and 3). Patients who had severe depression at baseline had higher fatigue scores compared to those with no depression after adjusting for baseline factors (Table 2). However, the association of depression with pain seen in the unadjusted model did not persist after adjustment. In contrast, patients with severe anxiety had high levels of pain compared to patients with no anxiety, and this effect persisted after adjusting for baseline factors; though anxiety did not have a substantial impact on fatigue (Table 3) after adjustment. Finally, we found that illness
belief, assessed by BIPQ, significantly influenced pain and fatigue scores but not DAS28-ESR (Table 4).

**Predictors of 12-Month DAS28-ESR Remission**

There was a strong relationship between obesity and remission. Mean BMI was higher in patients not in remission, compared to patients achieving DAS28-ESR remission (29.0 vs 26.0 kg/m², t-test p-value = 0.0004), Supplementary Table 2.

Baseline obesity (BMI >30 kg/m²) predicted remission at 12-months, and its impact persisted after adjusting for baseline factors (Table 1). Obese patients were less likely to achieve remission compared to those with BMIs <25 kg/m² (adjusted OR 0.34; 95% CI 0.16 - 0.69, p = 0.003). There were more remissions in patients randomised to the intensive management arm, as compared to standard care arm patients who had normal BMIs or were overweight; but there was no significant difference in obese patients (Figure 1). Further analysis of obese patients showed 5/26 (19%) patients with baseline BMIs of 30-35 kg/m² receiving intensive management achieved remission, as compared with 4/30 (13%) receiving standard care; but only 2/24 (8%) patients with BMIs >35 kg/m² receiving intensive management achieved remission, as compared with 1/14 (7%) receiving standard care.

Detailed analysis of the components of DAS28-ESR at 12 months and changes over 0-12 months (Supplementary Table 5) showed the final ESR was higher in obese patients, compared to those who were of normal weight or were overweight (mean 20.4 vs 13.9; p=0.001). Change in tender joint count, ESR and patient global assessment were lower in obese patients.
An additional analysis evaluated the effects of intensive treatment on changes in DAS28-ESR score in non-obese and obese patients. In non-obese patients, DAS28-ESR scores fell by 0.6 (95% CI 0.3, 0.9) with standard care and by 1.2 (95% CI 0.9, 1.4) with intensive management, and this difference was significant (p=0.007); in obese patients DAS28-ESR scores fell by 0.1 (95% CI -0.2, 0.4) with standard care and by 0.7 (95% CI 0.3, 1.1) with intensive management, and this difference was significant (p=0.020). However, final mean DAS28-ESR scores after intensive treatment were lower in non-obese patients (3.2; 95% CI 2.9, 3.5) than in obese patients (3.8; 95% CI 3.4, 4.1), which explains why there were fewer remissions in obese patients. Although the additional analysis shows a fall in DAS28-ESR amongst patients randomised to the intensive management arm, there was no interaction between baseline BMI and the trial arm when was examined in the multivariable model (interaction p-value = 0.482).

Mean depression score was higher in patients with active disease as compared to patients in remission (8.4, vs 7.9, p = 0.524) (Supplementary Table 2). Slightly more patients with active RA had severe depression (19%), as compared to those with quiescent disease (15%). However, regression analysis showed depression had no important impact on remission outcomes.

Mean anxiety score was higher in patients with active RA (5.4, SD 5.3) as compared to patients with quiescent disease (4.8, SD 5.3) (Supplementary Table 2), but similar proportions of patients had severe anxiety in the remission (7%) and non-remission groups (8%). Regression analysis showed anxiety had no important impact on disease outcomes. Finally, illness perception had no association on changes in pain or fatigue and remission rates (Table 4).
Predictors of 12-Month Improvements in Pain and Fatigue

No evidence of an association between BMI and pain scores were found. Mean baseline BMI was slightly lower in patients whose pain scores improved by ≥10 compared to <10 (27 vs 29 p = 0.094) (Supplementary Table 3). Slightly more patients with no reduction in pain levels were obese (34%), as compared to those who did (27%). However, regression analysis showed obesity had no significant impact on improvements in pain (Table 1). Baseline depression and anxiety scores were similar for patients regardless of pain outcomes. Regression analyses (Tables 3) showed anxiety scores had a borderline significant (p=0.046) impact on pain reduction.

BMI had a stronger relationship to improvements in fatigue. Mean baseline BMI was 27 (SD 6) in patients whose fatigue scores improved by ≥10, as compared with 29 (SD 8) in patients whose fatigue score improved by <10 (Supplementary Table 4). However, there was no evidence that categorised BMI was associated with clinically meaningful changes in pain outcomes. More patients who did not sustain reduction in pain levels were obese (34%), as compared to those who did (27%). Regression analysis showed obese patients were less likely to reduce fatigue scores as compared to those with BMI <25 kg/m² (Table 1). Mean baseline depression and anxiety scores were similar in patients regardless of fatigue outcomes (Supplementary Table 4). Tables 2 and 3 demonstrate that depression and anxiety scores had no significant impact on fatiguability.
DISCUSSION

Baseline obesity, depression and anxiety all influence RA clinical and psychological outcome measures, including disease activity, pain and fatigue. However, these symptoms have different impacts. Obese patients had higher overall disease activity measurements and fewer remissions. Obese patients also had higher overall pain and fatigue scores and were less likely to show improvements in fatigue. Anxious patients had higher overall pain levels, while depressed patients had higher overall fatigue scores. However, baseline anxiety and depression were unrelated to improvements in pain and fatigue and had no substantial relationships to RA disease activity level or remission induction.

There is growing recognition that obesity is closely associated with treatment failure and poorer outcomes of not achieving remission when receiving intensive management. Although an association was found between BMI and continuous DAS28-ESR score and remission, the impact of being overweight was minimal; whilst being obese, in particular, having a BMI >35 kg/m² were most clearly associated with a lack of remission. The majority of evidence on the relationship between obesity, disease activity and remission in RA comes from observational studies. A recent study by Schäfer et al (2020) exemplifies research in this field; they reported the impact of obesity on improvement in DAS28-ESR in 10,593 RA patients in an observational cohort treated with conventional DMARDs and biologics. Obesity reduced the impact of conventional DMARDs and cytokine inhibitors on DAS28-ESR and its components. There are similar findings in many other observational studies [5, 18-28]. In contrast, obesity had no impact on response to the cellular inhibitors rituximab and abatacept [29, 30]. Abuhelwa et al [31] found a similar impact of obesity on remission, as assessed using the Simple Disease Activity Index (SDAI) and Clinical Disease Activity Index
(CDAI), showing that the findings are not confined to assessments using the DAS28-ESR. Systematic reviews have summarised the overall impact of obesity in reducing remission in RA [31-36] Although there have been fewer analyses of the impact of obesity in clinical trials, those trials which have been analysed report similar findings [37-39] and have the advantage of being longitudinal.

There is uncertainty about why obesity reduces remission rate with conventional DMARDs and cytokine inhibitors. One possibility is that obese patients might have higher ESR levels, irrespective of their level of systemic inflammation [40]. Another possibility is that clinical assessment and measuring joint counts might be difficult in obese patients [41]. Although we found ESR to be higher in obese patients at 12 months, higher patient global assessment scores were also found, suggesting the impact of obesity on disease activity.

Our detailed analysis of DAS28-ESR change and intensive treatment indicate that obese patients respond to intensive management, but their level of response is reduced as compared to non-obese patients. This is also the case in patients receiving standard care.

The balance of evidence suggests that the difference is either because obese patients have more active disease, or that they are treated insufficiently, though a combination of both is possible. Traditionally the dose of DMARDs and cytokine inhibitors are not increased in obese patients, and it is possible this method is mistaken. Dosing by body weight might be a more accurate approach.

The impact of depression and anxiety is different from obesity. There was no evidence either had a major impact on disease activity. However, these two symptoms were associated with higher levels of pain and fatigue throughout treatment, with depression being most associated
with fatigue and anxiety with pain. In TITRATE, patient’s pain and fatigue improved with intensive management irrespective of whether they had pre-existing anxiety or depression. However, as the intervention involved both drug and non-drug supportive management, it is possible that the non-drug aspects of management helped reduce psychological symptoms and may have influenced pain and fatigue. This possibility was not evaluated in the trial. Our findings are in keeping with the extensive evidence that anxiety and depression are common in RA compared to the general population and they impact on a range of symptoms, including pain [42, 43]. The interaction between psychological status and disease status in RA is complex [11, 44], and our findings help clarify their impact.

Illness perceptions as assessed by the BIPQ, had a comparable impact with both depression and anxiety. All three factors had an influence on the level of pain and fatigue throughout the trial, but were not associated with a significant change in assessment of these factors at 12 months. Illness perception was also unrelated to DAS28-ESR scores and remission. Similar findings have broadly been reported in recent observational studies of patients with RA who received methotrexate [45] and more intensive treatment [46, 47] for early RA.

The strengths of this study include its sample size, the involvement of many different English centres, and the training of specialist nurses in providing supportive care. The impact of baseline factors on clinical outcomes were key and formed a considered part of the trial design. The study has several limitations. Firstly, PHQ-9, GAD-7 and BIPQ were only assessed at baseline; and there may have been changes during treatment which could have influenced their interactions with pain and fatigue. Secondly, the trial was not powered for the various secondary analyses; consequently, small but potentially important effects of the different predictors may not have been found. Thirdly, we have not assessed the interaction
between the different predictors. Although it is likely that assessments of psychological status and health beliefs are inter-related, this trial was too small to evaluate their interaction. A substantially larger study is needed to achieve this goal. Finally, BMI presents a relatively crude assessment of fat mass; the presence of sarcopenia influences the amount of lean body mass and contributes to frailty, which is itself is associated with poor clinical/psychological outcomes. Patients diagnosed with RA may have greatly reduced amounts of muscle. More detailed analyses are needed to evaluate this specific issue in detail.

CONCLUSIONS

We conclude that the outcome of RA treatment is influenced by a variety of factors, including obesity, depression, anxiety, and illness perceptions. There is a strong case to assess these factors, not only in routine practice but also in future trials of RA management. As obesity reduces remission with conventional DMARDs and cytokine inhibitors given in standard dosage regimens, there is a case for including assessments of baseline obesity in clinical trials of intensive management regimens in RA: Firstly, the extent of obesity may influence the numbers of remission obtained; Secondly, treatment intensity may need to be increased in obese patients.
REFERENCES

1. Scott DL, Steer S: The course of established rheumatoid arthritis. Best practice & research Clinical rheumatology 2007, 21(5):943-967.

2. Hughes CD, Scott DL, Ibrahim F: Intensive therapy and remissions in rheumatoid arthritis: a systematic review. BMC musculoskeletal disorders 2018, 19(1):389.

3. Martin NH, Ibrahim F, Tom B, Galloway J, Wailoo A, Tosh J, Lempp H, Prothero L, Georgopoulou S, Sturt J et al: Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial. Trials 2017, 18(1):591.

4. Scott D, Ibrahim F, Hill H, Tom B, Prothero L, Baggott RR, Bosworth A, Galloway JB, Georgopoulou S, Martin N: The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial. In: Seminars in arthritis and rheumatism: 2020: Elsevier; 2020: 1182-1190.

5. Nikiphorou E, Norton S, Young A, Dixey J, Walsh D, Helliwell H, Kiely P, Study ERA, Network tERA: The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Study/Early Rheumatoid Arthritis Network UK prospective cohorts. Rheumatology 2018, 57(7):1194-1202.

6. Matcham F, Norton S, Scott DL, Steer S, Hotopf M: Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatology (Oxford, England) 2016, 55(2):268-278.

7. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD et al: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the rheumatic diseases 2010, 69(9):1580-1588.

8. Georgopoulou S, Prothero L, Lempp H, Galloway J, Sturt J: Motivational interviewing: relevance in the treatment of rheumatoid arthritis? Rheumatology (Oxford, England) 2016, 55(8):1348-1356.

9. Prothero L, Georgopoulou S, de Souza S, Bosworth A, Bearne L, Lempp H: Patient involvement in the development of a handbook for moderate rheumatoid
**arthritis.** Health expectations: an international journal of public participation in health care and health policy 2017, 20(2):288-297.

10. Prothero L, Sturt J, de Souza S, Lempp H, Lempp H, Sturt J, Georgopoulou S, Prothero L, Neatrour I, Baggott R et al: Intensive management for moderate rheumatoid arthritis: a qualitative study of patients’ and practitioners’ views. BMC Rheumatology 2019, 3(1):12.

11. Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001, 16(9):606-613.

12. Spitzer RL, Kroenke K, Williams JB, Lowe B: A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of internal medicine 2006, 166(10):1092-1097.

13. Broadbent E, Petrie KJ, Main J, Weinman J: The brief illness perception questionnaire. Journal of psychosomatic research 2006, 60(6):631-637.

14. Wolfe F, Michaud K: Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. The Journal of rheumatology 2007, 34(8):1674-1683.

15. Khanna D, Pope JE, Khanna PP, Maloney M, Samedi N, Norrie D, Ouimet G, Hays RD: The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice. The Journal of rheumatology 2008, 35(12):2339-2343.

16. White IR, Moodie E, Thompson SG, Croudace T: A modelling strategy for the analysis of clinical trials with partly missing longitudinal data. Int J Methods Psychiatr Res 2003, 12(3):139-150.

17. StataCorp: Stata Statistical Software. In.: Release 16; College Station: TX: StataCorp LLC; 2019.

18. Schäfer M, Meißner Y, Kekow J, Berger S, Remstedt S, Manger B, Listing J, Strangfeld A, Zink A: Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis. Rheumatology 2020, 59(8):1916-1926.

19. Baganz L, Richter A, Albrecht K, Schneider M, Burmester G-R, Zink A, Strangfeld A: Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts. In: Seminars in arthritis and rheumatism: 2019: Elsevier; 2019: 976-982.
20. Cook MJ, Diffin J, Scire CA, Lunt M, MacGregor AJ, Symmons DP, Verstappen SM: Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. *Rheumatology* 2016, 55(9):1601-1609.

21. Di Carlo M, Salaffi F, Gremese E, Iannone F, Lapadula G, Ferraccioli G, Group GS: Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study. *European journal of internal medicine* 2019, 66:57-61.

22. Gardette A, Ottaviani S, Sellam J, Berenbaum F, Liroté F, Fautrel B, Palazzo E, Meyer A, Sibilia J, Dieudé P: Body mass index and response to abatacept in rheumatoid arthritis. *European journal of clinical investigation* 2016, 46(12):1048-1052.

23. Gardette A, Ottaviani S, Sellam J, Berenbaum F, Liroté F, Meyer A, Sibilia J, Fautrel B, Palazzo E, Dieudé P: Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. *Clinical rheumatology* 2016, 35(12):857-861.

24. Goossens J, Coustet B, Palazzo E, Dieudé P, Ottaviani S: Overweight and obesity affect clinical assessment of synovitis in rheumatoid arthritis: comparison of ultrasonography and clinical exam. *Clinical and experimental rheumatology* 2019, 37(1):49-54.

25. McCulley CB, Barton JL, Cannon GW, Sauer BC, Teng CC, George MD, Caplan L, England BR, Mikuls TR, Baker JF: Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis. *Clinical and experimental rheumatology* 2019, 37(3):422-428.

26. Ottaviani S, Gardette A, Roy C, Tubach F, Gill G, Palazzo E, Meyer O, Dieudé P: Body mass index and response to rituximab in rheumatoid arthritis. *Joint, bone, spine : revue du rhumatisme* 2015, 82(6):432-436.

27. Sandberg ME, Bengtsson C, Källberg H, Wesley A, Klareskog L, Alfredsson L, Saevarsdottir S: Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. *Annals of the rheumatic diseases* 2014, 73(11):2029-2033.

28. Sapundzhieva T, Karalilova R, Batalov A: Body mass index impact on disease activity, clinical and sonographic remission rates in patients with rheumatoid arthritis. *Current rheumatology reviews* 2019, 15(3):215-223.

29. Schulman E, Bartlett SJ, Schieir O, Andersen KM, Boire G, Pope JE, Hitchon C, Jamal S, Thorne JC, Tin D: Overweight, obesity, and the likelihood of achieving...
sustained remission in early rheumatoid arthritis: results from a multicenter prospective cohort study. *Arthritis care & research* 2018, 70(8):1185-1191.

30. Iannone F, Courvoisier DS, Gottenberg JE, Hernandez MV, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X: Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the “pan-European registry collaboration for abatacept (PANABA). *Clinical rheumatology* 2017, 36(4):773-779.

31. Abuhelwa AY, Hopkins AM, Sorich MJ, Proudman S, Foster DJ, Wiese MD: Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. *Scientific reports* 2020, 10(1):1-9.

32. Lee YX, Kwan YH, Lim KK, Tan CS, Lui NL, Phang JK, Chew EH, Ostbye T, Thumboo J, Fong W: A systematic review of the association of obesity with the outcomes of inflammatory rheumatic diseases. *Singapore medical journal* 2019, 60(6):270.

33. Liu Y, Hazlewood GS, Kaplan GG, Eksteen B, Barnabe C: Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. *Arthritis care & research* 2017, 69(2):157-165.

34. Lupoli R, Pizzicato P, Scalera A, Ambrosino P, Amato M, Peluso R, Di Minno MND: Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. *Arthritis research & therapy* 2016, 18(1):1-9.

35. Shan J, Zhang J: Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis. *Joint, bone, spine : revue du rhumatisme* 2019, 86(2):173-183.

36. Singh S, Facciorusso A, Singh AG, Casteele NV, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ: Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. *PloS one* 2018, 13(5):e0195123.

37. Vidal C, Barnetche T, Morel J, Combe B, Daïen C: Association of body mass index categories with disease activity and radiographic joint damage in rheumatoid arthritis: a systematic review and metaanalysis. *The Journal of rheumatology* 2015, 42(12):2261-2269.
38. D’Agostino M-A, Alten R, Mysler E, Le Bars M, Ye J, Murthy B, Heitzmann J, Vadanici R, Ferraccioli G: **Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.** *Clinical rheumatology* 2017, 36(12):2655-2665.

39. George MD, Østergaard M, Conaghan PG, Emery P, Baker DG, Baker JF: **Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis.** *Annals of the rheumatic diseases* 2017, 76(10):1743-1746.

40. Levitsky A, Brismar K, Hafstrom I, Hambardzumyan K, Lourdudoss C, van Vollenhoven RF, Saevarsdottir S: **Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial.** *RMD open* 2017, 3(2):e000458.

41. George MD, Giles JT, Katz PP, England BR, Mikuls TR, Michaud K, Ogdie-Beatty AR, Ibrahim S, Cannon GW, Caplan L: **Impact of obesity and adiposity on inflammatory markers in patients with rheumatoid arthritis.** *Arthritis care & research* 2017, 69(12):1789-1798.

42. Courties A, Sellam J: **Disconnect in the effects of obesity on RA outcomes.** *Nature Reviews Rheumatology* 2016, 12(9):501-502.

43. Matcham F, Rayner L, Steer S, Hotopf M: **The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis.** *Rheumatology (Oxford, England)* 2013, 52(12):2136-2148.

44. Rayner L, Matcham F, Hutton J, Stringer C, Dobson J, Steer S, Hotopf M: **Embedding integrated mental health assessment and management in general hospital settings: feasibility, acceptability and the prevalence of common mental disorder.** *General hospital psychiatry* 2014, 36(3):318-324.

45. Rathbun AM, Reed GW, Harrold LR: **The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review.** *Rheumatology (Oxford, England)* 2013, 52(10):1785-1794.

46. Gwinnutt JM, Norton S, Hyrich KL, Lunt M, Barton A, Cordingley L, Verstappen SM: **Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy.** *Rheumatology* 2020.

47. Van der Elst K, Verschueren P, De Cock D, De Groef A, Stouten V, Pazmino S, Vriezekolk J, Joly J, Moons P, Westhovens R: **One in five patients with rapidly and**
persistently controlled early rheumatoid arthritis report poor well-being after 1 year of treatment. *RMD open* 2020, 6(1):e001146.
### Table 1: Influence of baseline BMI on RA disease activity, pain and fatigue over 12 months

|                      | Crude          | Adjusted*       |
|----------------------|----------------|-----------------|
|                      | β (95%CI)      | p-value         | β (95%CI)      | p-value         |
| **Average Scores (0, 6 And 12 Months)** |                |                 |                |                 |
| **DAS28-ESR**        |                |                 |                |                 |
| Normal               | Reference      | Reference       | Reference      | Reference       |
| Overweight           | 0.15 (-0.07, 0.38) | 0.181           | 0.08 (-0.15, 0.31) | 0.506           |
| Obese               | 0.38 (0.14, 0.61) | 0.002           | 0.29 (0.05, 0.53) | 0.017           |
| **Pain**             |                |                 |                |                 |
| Normal               | Reference      | Reference       | Reference      | Reference       |
| Overweight           | 6.00 (0.86, 11.13) | 0.022           | 5.17 (0.29, 10.05) | 0.038           |
| Obese               | 8.48 (3.36, 13.60) | 0.001           | 8.16 (3.12, 13.21) | 0.002           |
| **Fatigue**          |                |                 |                |                 |
| Normal               | Reference      | Reference       | Reference      | Reference       |
| Overweight           | 3.59 (-2.61, 9.79) | 0.256           | 3.36 (-2.05, 8.77) | 0.224           |
| Obese               | 7.96 (1.86, 14.05) | 0.010           | 5.66 (0.02, 11.30) | 0.049           |
| **12 Month Outcomes**|                |                 |                |                 |
| **Remission DAS28-ESR (<2.6)** |              |                 |                |                 |
| Normal               | Reference      | Reference       | Reference      | Reference       |
| Overweight           | 0.95 (0.52, 1.70) | 0.853           | 0.97 (0.50, 1.87) | 0.925           |
| Obese               | 0.32 (0.15, 0.67) | 0.002           | 0.33 (0.16, 0.72) | 0.005           |
| **Change in Pain (≥10 units)** |            |                 |                |                 |
| Normal               | Reference      | Reference       | Reference      | Reference       |
| Overweight           | 1.00 (0.58, 1.72) | 0.996           | 1.11 (0.62, 2.00) | 0.719           |
| Obese               | 0.74 (0.42, 1.29) | 0.287           | 0.68 (0.37, 1.24) | 0.213           |
| **Change in Fatigue (≥10 units)** |            |                 |                |                 |
| Normal               | Reference      | Reference       | Reference      | Reference       |
| Overweight           | 0.69 (0.40, 1.18) | 0.172           | 0.76 (0.42, 1.37) | 0.362           |
| Obese               | 0.53 (0.30, 0.94) | 0.029           | 0.53 (0.29, 0.98) | 0.043           |

*Adjustment for age, gender, ethnicity, disease duration, NHS region and trial arm
Table 2: Influence of Depression on RA disease activity, pain and fatigue over 12 months

|                      | Average Scores (0, 6 And 12 Months) | 12 Month Outcomes |
|----------------------|-------------------------------------|-------------------|
|                      | Crude | Adjusted* |
|                      | **β (95%CI)** | **p-value** | **β (95%CI)** | **p-value** |
|                      | **β (95%CI)** | **p-value** | **β (95%CI)** | **p-value** |
|                      |       |           |       |           |
| **DAS28-ESR**        |       |           |       |           |
| None                 | Reference | Reference |
| Moderate             | 0.13 (-0.10,0.36) | 0.278 | 0.07 (-0.19,0.33) | 0.595 |
| Severe               | 0.24 (0.02,0.46) | 0.030 | 0.03 (-0.29,0.36) | 0.838 |
| **Pain**             |       |           |       |           |
| None                 | Reference | Reference |
| Moderate             | 5.72 (0.66,10.77) | 0.027 | 0.88 (-4.49,6.25) | 0.749 |
| Severe               | 11.88 (7.06,16.71) | <0.001 | -0.88 (-7.57,5.81) | 0.796 |
| **Fatigue**          |       |           |       |           |
| None                 | Reference | Reference |
| Moderate             | 13.12 (7.33,18.91) | <0.001 | 10.13 (4.20,16.07) | 0.001 |
| Severe               | 24.76 (19.56,29.96) | <0.001 | 17.07 (9.76,24.37) | <0.001 |
| **Remission DAS28-ESR (<2.6)** |       |           |       |           |
| None                 | Reference | Reference |
| Moderate             | 1.28 (0.62,2.65) | 0.500 | 1.43 (0.64,3.19) | 0.377 |
| Severe               | 0.78 (0.37,1.62) | 0.498 | 0.77 (0.35,1.73) | 0.535 |
| **Change in Pain (≥10 units)** |       |           |       |           |
| None                 | Reference | Reference |
| Moderate             | 0.89 (0.46,1.72) | 0.726 | 0.66 (0.31,1.37) | 0.264 |
| Severe               | 1.17 (0.64,2.13) | 0.608 | 1.19 (0.62,2.29) | 0.597 |
| **Change in Fatigue (≥10 units)** |       |           |       |           |
| None                 | Reference | Reference |
| Moderate             | 1.61 (0.84,3.11) | 0.152 | 1.59 (0.76,3.34) | 0.219 |
| Severe               | 1.25 (0.68,2.28) | 0.469 | 1.40 (0.72,2.73) | 0.321 |

*Adjustment for age, gender, ethnicity, disease duration, NHS region and trial arm
Table 3: Influence of anxiety on RA disease activity, pain and fatigue over 12 months

| DAS28-ESR | Average Scores (0, 6 And 12 Months) | Crude | Adjusted* |
|-----------|-------------------------------------|-------|-----------|
|           | **β (95%CI)** | **p-value** | **β (95%CI)** | **p-value** |
| **None**  | Reference          |       | Reference          |       |
| **Moderate** | 0.19 (-0.04,0.42) | 0.097 | 0.14 (-0.15,0.42) | 0.340 |
| **Severe** | 0.34 (0.11,0.57)  | 0.003 | 0.32 (-0.03,0.66) | 0.071 |

| Pain      | Crude | Adjusted* |
|-----------|-------|-----------|
|           | **β (95%CI)** | **p-value** | **β (95%CI)** | **p-value** |
| **None**  | Reference          |       | Reference          |       |
| **Moderate** | 9.05 (4.01,14.09) | <0.001 | 3.44 (-2.76,9.63) | 0.277 |
| **Severe** | 15.03 (9.60,20.47) | <0.001 | 9.60 (2.30,16.90) | 0.010 |

| Fatigue   | Crude | Adjusted* |
|-----------|-------|-----------|
|           | **β (95%CI)** | **p-value** | **β (95%CI)** | **p-value** |
| **None**  | Reference          |       | Reference          |       |
| **Moderate** | 15.15 (9.62,20.68) | <0.001 | 0.22 (-6.56,7.00) | 0.949 |
| **Severe** | 21.42 (15.08,27.76) | <0.001 | 3.12 (-4.39,10.62) | 0.415 |

| 12 Month Outcomes | Crude | Adjusted* |
|-------------------|-------|-----------|
| Remission DAS28-ESR (<2.6) | Crude | Adjusted* |
|                   | **Odds Ratio (95%CI)** | **p-value** | **Odds Ratio (95%CI)** | **p-value** |
| **None**  | Reference          |       | Reference          |       |
| **Moderate** | 0.74 (0.29, 1.89)  | 0.528 | 0.72 (0.25, 2.10) | 0.549 |
| **Severe** | 0.79 (0.28, 2.20)  | 0.647 | 0.98 (0.33, 2.92) | 0.968 |

| Change in Pain (≥10 units) | Crude | Adjusted* |
|---------------------------|-------|-----------|
|                   | **Odds Ratio (95%CI)** | **p-value** | **Odds Ratio (95%CI)** | **p-value** |
| **None**  | Reference          |       | Reference          |       |
| **Moderate** | 0.51 (0.22, 1.16)  | 0.110 | 0.46 (0.19, 1.11) | 0.083 |
| **Severe** | 2.43 (0.96, 6.16)  | 0.061 | 2.88 (0.98, 7.94) | 0.046 |

| Change in Fatigue (≥10 units) | Crude | Adjusted* |
|-----------------------------|-------|-----------|
|                   | **Odds Ratio (95%CI)** | **p-value** | **Odds Ratio (95%CI)** | **p-value** |
| **None**  | Reference          |       | Reference          |       |
| **Moderate** | 1.11 (0.51, 2.40)  | 0.790 | 1.12 (0.48, 2.62) | 0.785 |
| **Severe** | 0.99 (0.41, 2.38)  | 0.985 | 1.41 (0.54, 3.69) | 0.488 |

*Adjustment for age, gender, ethnicity, disease duration, NHS region and trial arm
Table 4: Influence of illness perception on RA disease activity, pain and fatigue over 12 months

|                          | Crude          |       | Adjusted* |       |
|--------------------------|----------------|-------|-----------|-------|
|                          | β (95%CI)      | p-value | β (95%CI) | p-value |
| **Average Scores (0, 6 And 12 Months)** |                |       |           |       |
| DAS28-ESR                | 0.01 (-0.001,0.02) | 0.088 | 0.007 (-0.01, 0.02) | 0.306 |
| Pain                     | 0.73 (0.50,0.96) | <0.001 | 0.62 (0.36,0.88) | <0.001 |
| Fatigue                  | 0.96 (0.68,1.24) | <0.001 | 0.51 (0.20,0.82) | 0.001 |
| **12 Month Outcomes**    |                |       |           |       |
| Remission DAS28-ESR (<2.6) | 1.00 (0.97,1.03) | 0.969 | 1.01 (0.96,1.03) | 0.808 |
| Change in Pain (≥10 units) | 1.01 (0.98,1.03) | 0.667 | 1.00 (0.98,1.02) | 0.642 |
| Change in Fatigue (≥10 units) | 1.01 (0.99,1.04) | 0.353 | 1.02 (0.98,1.04) | 0.387 |

*Adjustment for age, gender, ethnicity, disease duration, NHS region and trial arm
Figure 1: Impact of Baseline BMI on 12 Month DAS28-ESR Remission by Obesity Status

Legend for Figure 1
BMI: Normal <25 kg/m², Overweight 25-30 kg/m², Obese >35 kg/m². Significance by Fisher’s Exact Test